Understanding the role of IL-17 in Bullous Pemphigoid
Identification and Functional Characterization of the Cellular and Molecular Actors of the IL-17B/IL-17RB Axis in Bullous Pemphigoid
This study is testing how a specific immune response related to IL-17 affects people with bullous pemphigoid to see if it can help improve treatment options.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Trial ID | NCT06479018 on ClinicalTrials.gov |
What this trial studies
This study focuses on bullous pemphigoid, an autoimmune skin disease primarily affecting the elderly, characterized by blisters and intense itching. It aims to investigate the IL-17B/IL-17RB inflammatory response in patients diagnosed with this condition. By recruiting 90 patients from the Reims University Hospital, the study will analyze cellular and molecular factors associated with IL-17 and their role in the disease's pathophysiology. Additionally, it seeks to identify IL-17B as a potential biomarker for treatment outcomes and to understand the inflammatory profile of different clinical variants of bullous pemphigoid.
Who should consider this trial
Good fit: Ideal candidates are elderly patients diagnosed with bullous pemphigoid who meet specific clinical and laboratory criteria.
Not a fit: Patients with pemphigoid gestationis or those who have recently received corticosteroid treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more targeted therapies for bullous pemphigoid, reducing side effects associated with current treatments.
How similar studies have performed: While the role of IL-17 in autoimmune diseases is being explored, this specific approach to bullous pemphigoid is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with Bullous Pemphigoid (BP) using the following criteria: clinical features typical of BP with presence of at least three out of four well-established criteria by Vaillant et al.47; subepidermal blister on skin biopsy; and deposits of IgG and/or C3 in a linear pattern along the epidermal basement membrane zone by direct IF. * patient agreed to participate to the study * patient affiliated to the French Healthcare System Exclusion Criteria: * patient that does not have the ability to give its written informed consent before inclusion in the study * patient with a pemphigoid gestationis * patient with a relapse of Bullous Pemphigoid * patient with Bullous Pemphigoid that already received local superpotent corticotherapy during the last 14 days before inclusion or systemic corticoid treatment during the last 28 days before inclusion * anemic patient (hemoglobin \< 10 g/dL)
Where this trial is running
Reims
- Chu Reims — Reims, France (Recruiting)
Study contacts
- Study coordinator: Manuelle VIGUIER, Pr.
- Email: mviguier@chu-reims.fr
- Phone: 03.10.73.66.76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.